Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients

BMC Endocrine Disorders

Tamer Tetiker¹  Murat Sert¹  Mehtap Evran¹ 

[1] Department of Internal Medicine, Division of Endocrinology, Balcali Hospital, Cukurova University Medical Faculty, 01330 Adana, Turkey

关键词: Pituitary hormone deficiency;    IGF-1;    GH;    Treatment;    Diagnosis;    Acromegaly;   

Others  :  1084676
DOI  :  10.1186/1472-6823-14-97

 received in 2014-08-02, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

This study aimed to report the clinical and outcome data from a large cohort of patients diagnosed with acromegaly and treated at our institution over a 20-year period.

Methods

Sixty-two acromegaly patients (32 women and 30 men) treated and monitored at the endocrinology polyclinic between 1984 and 2013 were enrolled in this retrospective study. Clinical features and patients’ treatment outcomes were evaluated. A level of growth hormone (GH) of <2.5 ng/ml was considered as the criterion for remission, and the normal insulin-like growth factor (IGF) range was based on gender and age.

Results

The mean age at the time of diagnosis was 38.8 ± 1.4 years, the time to diagnosis was 4.5 ± 0.3 years, and the follow-up duration was 7.3 ± 0.8 years. Among patients’ symptoms, growth in hands and feet and typical facial dysmorphism were the most prominent (92%). The number of patients with diabetes mellitus, hypertension and hyperprolactinemia were 22 (35%), 13 (21%) and 13 (21%), respectively. Microadenomas and macroadenomas were found in eight and 54 patients, respectively. A significant correlation was found between the initial tumor diameters and GH levels (p = 0.002). The mean GH and IGF-1 levels were 39.18 ± 6.1 ng/ml and 993.5 ± 79 ng/ml, respectively. Visual field defect was found in 16 patients (32%). Thirty-one patients were treated by transsphenoidal surgery. Four of these were cured, 10 patients developed postoperative anterior pituitary hormone deficiency, and one patient developed diabetes insipidus. Twenty patients were treated by transcranial surgery, of which two were cured, while 17 patients developed postoperative anterior pituitary hormone deficiency. In total, five of the patients who were not cured after surgery were given conventional radiotherapy, of which two were cured. Four of 15 patients, on whom Gamma Knife radiosurgery was performed, were cured. Biochemical remission was achieved in 32 of 52 patients who received octreotide treatment, and in two of five patients who received lanreotide treatment.

Conclusions

The rate of surgical success in our patients was found to be low. This could be explained by an absence of experienced pituitary surgical centers or surgeons in our region, and the fact that most patients presented late at the macroadenoma stage.

【 授权许可】

   
2014 Evran et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Holdaway IM, Rajasoorya C: Epidemiology of acromegaly. Pituitary 1999, 2:29-41.
• [2]Colao A, Ferone D, Marzullo P, Lombardi G: Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25:102-152.
• [3]Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G: Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 2008, 14:3484-3489.
• [4]Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly; a retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab 1998, 83:2730-2734.
• [5]Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A: Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87:4054-4058.
• [6]Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group: A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
• [7]Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, Hubalewska-Dydejczyk : A Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011, 14:157-162.
• [8]ᅟ: From TIETZ’s fundamentals of clinical chemistry. 6th edition. Edited by Burtis CA, Ashwood ER, Bruns DE. Philadelphia: Saunders Elsevier; 2007.
• [9]Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A: Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 2008, 93(Suppl 6):2035-2041.
• [10]Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988, 223(Suppl 4):327-335.
• [11]Lugo G, Pena L, Cordido F: Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol 2012, ᅟ:10.
• [12]Kreze A, Kreze-Spirova E, Mikulecky M: Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001, 34(Suppl 11):1429-1433.
• [13]Biering H, Knappe G, Gerl H, Lochs H: Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 2000, 27(Suppl 1):27-31.
• [14]Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A: Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000, 85(Suppl 1):193-199.
• [15]Melmed S, Kronenberg HM: Anterior pituitary from Wiiliams textbook of endocrinology. 11th edition. Edited by Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Philadelphia: Saunders Elsevier; 2008:209-223.
• [16]Barkan AL, Stred SE, Reno K: Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 1989, 69(Suppl 6):1225-1233.
• [17]Andersen M: GH excess: diagnosis and medical therapy. Eur J Endocrinol 2014, 170:31-41.
• [18]Chanson P, Salenave S: Acromegaly. Orphanet J Rare Dis 2008, 3:1-17. BioMed Central Full Text
• [19]Moyes V, Metcalfe K, Drake W: Clinical use of cabergoline as primary and andjunctive treatment for acromegaly. Eur J Endocrinol 2008, 159(Suppl 5):541-545.
• [20]AACE Acromegaly Guidelines Task Force: AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004, 10:213-225.
• [21]Daud S, Hamrahian AH, Weil RJ, Hamaty M, Prayson RA, Olansky L: Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? Pituitary 2011, 14(Suppl 4):414-417.
• [22]Giustina A, Barkan A, Casanueva FF, Cavagni F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85(Suppl 2):526-529.
• [23]Cordero RA, Barkan AL: Current diagnosis of acromegaly. Rev Endocrine Metab Dis 2008, 9(Suppl 1):13-19.
• [24]Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94:1509-1517.
• [25]Gittoes NJL, Sheppard MC, Johnson AP, Stewart PM: Outcome of surgery for acromegaly—the experience of a dedicated pituitary surgeon. QJM 1999, 92(Suppl 12):741-745.
• [26]Sheaves R, Jenkins P, Blackburn P, Huneidi AH: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996, 45(Suppl 4):407-413.
• [27]Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83(Suppl 10):3419-3426.
• [28]Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S: Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary 2005, 8(Suppl 2):93-97.
• [29]Bates PR, Carson MN, Trainer PJ: Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol 2008, 68(Suppl 1):136-142.
• [30]Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005, 152:379-387.
• [31]Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G: Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006, 91:1397-1403.
• [32]Powell JS, Wardlaw SL, Post KD, Freda PU: Outcome of radiotherapy for acromegaly using normalization of ınsulin-like growth factor ı to define cure. J Clin Endocrinol Metab 2000, 85(Suppl 5):2068-2071.
• [33]Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005, 62:210-216.
• [34]Pollock BE, Jacob JT, Brown PD, Nippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007, 106:833-838.
• [35]Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J: Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008, 93:2984-2990.
• [36]Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM: Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003, 88(Suppl 7):3090-3098.
• [37]Colao A, Renata SA, Galdiero M, Lombardi G, Pivonello R: Effects of ınitial therapy for five years with somatostatin analogs for acromegaly on growth hormone and ınsulin-like growth factor-ı levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009, 94(Suppl 10):3746-3756.
• [38]Ayuk J, Stewart SE, Stewart PM, Sheppard MC: Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002, 87(Suppl 9):4142-4146.
• [39]Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S: The ımplication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005, 90(Suppl 11):6290-6295.
• [40]Al-Maskari M, Gebble J, Kendall-Taylor P: The effect of a new slow-release, long-acting somatostatin analogue, lanreotide in acromegaly. Clin Endocrinol 1996, 45:415-421.
• [41]Turner HE, Vadivale A, Keenan J, Wass JAH: A comparison of Lanreotide and Octreotide LAR for treatment of acromegaly. Clin Endocrinol 1999, 51:275-280.
• [42]Ozturk FY, Cil E, Ozderya A, Karaman O, Zuhur SS, Altuntas Y: Unsatisfied treatment outcomes of acromegaly patients: a single center experience in Turkey. Endocrin Abstract 12th Eur Cong Endocrinol 2010, 22:569.
• [43]Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M: Ocreotide LAR treatment of acromegaly in “real life”:longterm outcome at tertiary care center. ᅟ: Publishing Springer; 2014. [e-mail]. Pituitary, Published Online: 30 April